Allergic eye disease: Blocking LTB4/C5 in vivo suppressed disease and Th2 & Th9 cells.

Eskandarpour, Malihe; Zhang, Xiaozhe; Micera, Alessandra; Zaher, Sarah; Larkin, Frank D P; Nunn, Miles; Bonini, Stefano; Weston-Davies, Wynne; Calder, Virginia L

Eskandarpour, Malihe; Zhang, Xiaozhe; Micera, Alessandra; Zaher, Sarah; Larkin, Frank D P; Nunn, Miles; Bonini, Stefano; Weston-Davies, Wynne; Calder, Virginia L.

Afiliación

Eskandarpour M; Ocular Immunology Group, UCL Institute of Ophthalmology, London, UK.
Zhang X; Ocular Immunology Group, UCL Institute of Ophthalmology, London, UK.
Micera A; UOSD Research Laboratories, IRCCS-fondazione Bietti, University Campus Bio-Medico, Rome, Italy.
Zaher S; NIHR Moorfields Clinical Research Facility, Moorfields Eye Hospital, London, UK.
Larkin FDP; NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust &, UCL Institute of Ophthalmology, London, UK.
Nunn M; NIHR Moorfields Clinical Research Facility, Moorfields Eye Hospital, London, UK.
Bonini S; NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust &, UCL Institute of Ophthalmology, London, UK.
Weston-Davies W; Akari Therapeutics plc, London, UK.
Calder VL; Ophthalmology Operative Complex Unit, University Campus Bio-Medico, Rome, Italy.

Allergy ; 77(2): 660-664, 2022 02.

Article en En | MEDLINE | ID: mdl-34614221

Asunto(s)

Oftalmopatías; Hipersensibilidad; Humanos; Leucotrieno B4; Linfocitos T Colaboradores-Inductores; Células Th2

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Oftalmopatías / Hipersensibilidad Límite: Humans Idioma: En Revista: Allergy Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google